Sera Prognostics announces PRIME preterm-birth study accepted for peer-reviewed publication

SERA PROGNOSTICS, INC.

PRIME study findings accepted for publication, following late-breaking abstract at SMFM annual meeting in 2025.
Study is one of the largest on preterm birth evaluating risk assessment plus clinical interventions.
Company expects to share manuscript data at medical meetings and with research analysts.
No financial terms or specific study results disclosed in this announcement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.